Full Text View
Tabular View
No Study Results Posted
Related Studies
Progesterone Treatment in Female Smokers - 12
This study has been completed.
Study NCT00000295   Information provided by National Institute on Drug Abuse (NIDA)
First Received: September 20, 1999   Last Updated: November 3, 2005   History of Changes

September 20, 1999
November 3, 2005
April 1999
 
  • Behavioral
  • Subjective
  • Biochemical
Same as current
Complete list of historical versions of study NCT00000295 on ClinicalTrials.gov Archive Site
 
 
 
Progesterone Treatment in Female Smokers - 12
Progesterone Treatment in Female Smokers

The purpose of this study is to investigate progesterone effects in female smokers

Limited research has been done on the effects of gender and menstrual cycle in response to drugs of abuse in humans. The main goal of this pilot study is to investigate the safety and tolerability of progesterone treatment in female nicotine users. In addition, plasma progesterone levels reached with a single 200 mg dose of progesterone treatment will be measured. The study will be a double-blind placebo controlled, crossover trial in which 12 female smokers who are in the early follicular phase of their menstrual cycle will be enrolled. Druing the experimental sessions, subjects will be given a single 200 mg dose of micronized progesterone or placebo and multiple blood samples will be obtained to measure the plasma levels of progesterone. Starting 2 hours after progesterone or placebo treatment, subjects will have a self-administration period that will last around 2.5 hours. We hypothesize that administration of 200 mg of progesterone will achieve plasma progesterone concentrations similar to those found in the luteal phase of the menstrual cycle, 3-30 ng/ml.

Phase II
Interventional
Treatment, Double-Blind, Placebo Control, Crossover Assignment
Tobacco Use Disorder
Drug: Micronized Progesterone
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
0
December 2001
 

Inclusion Criteria:

Female subjects aged 21-45 years with a smoking history of at least 20 cigarettes daily for at least 1 year. In good health as verified by medical history, screening examination, and screening laboratory tests. Not pregnant as determined by pregnancy screening nor breast feeding, and using acceptable birth control methods other than hormonal contraceptives.

Exclusion Criteria:

History of heart disease, peripheral vascular disease, COPD, liver diseases, abnormal vaginal bleeding, suspected or known breast malignancy, or any other medical condition which physician investigator deems inappropriate for subject participation. Use of regular psychotropic medication (antidepressants, antipsychotics, or anxiolytics) and recent psychiatric history. Amenorrhea. Current use of oral or other types of hormonal contraceptives. Abuse of alcohol or any other recreational or prescription drug. Regular use of any other tobacco products, including smokeless tobacco and nicotine products. Known allergy to progesterone or peanuts.

Female
21 Years to 45 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00000295
 
NIDA-09259-12, P50-09259-12
National Institute on Drug Abuse (NIDA)
University of Minnesota
Principal Investigator: Dorothy Hatsukami, Ph.D. University of Minnesota
National Institute on Drug Abuse (NIDA)
April 1999

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP